Arasali, Baby Boy .
HRN: 21-35-20 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/24/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/24/2022
06/01/2022
IVTT
35mg
Q24
MSAF, Thinly
Waiting Final Action
Indication: Empiric Type of Infection: Unspecified Sepsis Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes